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     Sarcopenia results in an increase in intermuscular fat (IMF) and low density 
muscle (LDM), which is associated with adverse health and functional consequences.   
Although strength training (ST) is considered an intervention of choice for the 
prevention and treatment of sarcopenia, little is known about its effect on IMF or 
LDM. Regional fat alterations resulting from exercise interventions may be 
influenced by adrenergic receptor (ADR) β2 Gln27Glu and ADRα2b Glu12/Glu9 gene 
polymorphisms. To examine the influence of this polymorphism on mid-thigh IMF, 
LDM and normal density muscle (NDM), we studied 46 older men and 52 older 
women before and after a 10-week single leg knee extension strength training (ST) 
program. The ST program resulted in a substantial increase in one-repetition 
maximum (1-RM) strength (P = 0.0001) and NDM (P = 0.0001), but no significant 
changes in IMF and LDM in the whole group. However, IMF was significantly 
reduced with ST in subjects carrying ADRβ2 Glu27 (-2.3 cm2, P = 0.028), but no 
significant change was observed with ADRβ2 Glu27 noncarriers (+1.5 cm2, P = 
0.14). The decrease in IMF in those with the ADRα2b Glu9 allele was approaching 
significance (-1.9 cm2, P = 0.066), and significantly different (-2.9 cm2, P = 0.043)  
from a nonsignificant increase in IMF in the ADRα2b Glu9 allele noncarriers. ADRβ2 
Glu27 carriers who also carried the ADRα2b Glu9 allele experienced a significant 
loss of IMF with ST (-3.8 cm2 ± 1.6, P = 0.018). These results suggest that the 
response of IMF to ST is influenced by ADRβ2 Gln27Glu and ADRα2b Glu12/Glu9 
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     Sarcopenia is the age-associated loss of muscle mass and strength. These losses 
are also associated with a deterioration in health status and with adverse effects on 
functional abilities in the elderly (1). Aging adversely affects the quality, as well as 
the quantity, of skeletal muscle (SM). For example, in African American women, fat 
infiltration of muscle increases with age (2), leading to the  accumulation of 
intermuscular fat (IMF) and the development of low density muscle (LDM). Elevated 
levels of  thigh IMF have been linked to insulin resistance in muscle and to the 
development of type 2 diabetes (3, 4). In addition, higher LDM is associated with  
lower muscle strength (5), with poorer leg function (6) and with greater incidence of 
mobility limitations in the elderly (7). 
     Despite this relationship of limb IMF and LDM to health and functional status and 
that ST is now commonly prescribed for the prevention and treatment of sarcopenia 
(8), little or no information is available on the effects of ST on limb IMF or LDM.  In 
this regard, Sipila et al. (9) reported a reduced percent of thigh IMF in response to ST, 
but no information on absolute IMF change was provided. The reduced percentage of 
fat may have just been due to the increase in thigh muscle mass, which lowers the 
percent of fat tissue, even if the total mass of fat doesn’t change.  One study showed 
that the combination of ST with aerobic exercise training decreased LDM (10) and 
another study showed that ST together with a low-calorie diet reduced thigh IMF 
(11). Unfortunately, neither of these two studies can tell us the independent effects of 
ST on IMF or LDM.   Thus, the first purpose of this study was to examine the effects 
of ST on IMF and LDM.  
1 
 
     ST has been showed to increase sympathetic nerve activity (12). Norepinephrine 
(NE) derived from sympathetic nerves regulates lipolysis by binding to stimulatory 
adrenergic receptors (ADR) (β1, 2, or 3), mainly ADRβ2 in skeletal muscle (13), and 
inhibitory ADRα2b receptors.  The balance between ADRβ2 and ADRα2b can thus 
determine the relative efficacy of NE as a lipolytic hormone. ADRβ2 Gln27Glu 
polymorphisms have been associated with fat adaptation to exercise training in some 
(14, 15), but not all studies (16).  The combined effects of ADRβ2 Gln27Glu and 
ADRα2b Glu12/Glu9 polymorphisms on the total body fat reduction induced by 
aerobic exercise training (15). However, studies investigating genotype influences of 
ST effects on fat phenotypes are unavailable. Thus, the second purpose of this study 
was to investigate ADR genotype influences on IMF and LDM responses to ST. We 
hypothesized that ST will significantly reduce IMF and LDM, and ADRβ2 and 











     Ninety-eight relatively healthy, sedentary, Caucasian (n = 67) and African 
American (n = 31) men (n = 46) and women (n =52) aged 50-85 years served as 
subjects for this study.  All subjects underwent a phone-screening interview, received 
medical clearance from their primary care physician and completed a detailed 
medical history prior to participation.  They were nonsmokers, free of significant 
cardiovascular, metabolic, or musculoskeletal disorders that would affect their ability 
to safely perform heavy resistance exercise.  Subjects who were already taking 
medications for at least three weeks prior to the start of the study were permitted into 
the study as long as they did not change medications or dosages at any time 
throughout the study.  After all methods and procedures were explained, subjects read 
and signed a written consent form, which was approved by the Institutional Review 
Board of the University of Maryland, College Park.  All subjects were continually 
reminded throughout the study not to alter their regular physical activity levels or 
dietary habits for the duration of the study, and body weight was measured weekly 
throughout the study to help confirm compliance to maintaining a stable diet. 
Genotyping 
     Genomic DNA was prepared from EDTA-anticoagulated whole blood samples by 
standard salting-out procedures (Puregene DNA Extraction, Gentra systems Inc). A 
restriction fragment length polymorphism (RFLP) procedure (17) was used to 
genotype for ADRβ2 Gln27Glu polymorphism using Fnu4H restriction enzyme. 
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ADRα2b polymorphisms were analyzed directly on 3% agarose gel for 3 hours at 100 
V for maximum separation and clarity. The genotype procedures were validated by 
direct sequencing of a random collection of samples. 
Body composition assessment 
     Body composition was estimated by dual-energy x-ray absorptiometry (DXA) 
using the fan-beam technology (model QDR 4500A, Hologic, Waltham, MA).  A 
total body scan was performed at baseline and again after the ST program using 
standardized procedures.  Hologic version 8.21 software for tissue area assessment 
was used to analyze for total body fat-free mass (FFM), fat mass, and % fat.  Total 
body FFM was defined as lean soft tissue mass plus total body bone mineral content 
(BMC).  The coefficients of variation (CV) for all DXA measures of body 
composition were calculated from repeated scans of 10 subjects who were scanned 
three consecutive times with repositioning.  The CV was 0.6 % for FFM and 1.0% for 
% fat.   
CT of the Mid-thigh 
     An axial computed tomography (CT) imaging of the trained and untrained mid-
thighs was obtained (GE Lightspeed Qxi, General Electric, Milwaukee) at baseline 
and during the last week of the 10-week unilateral ST program.  Mid-thigh was 
defined as mid-point of the most distal point of the ischial tuberosity to the most 
proximal part of the patella, while subjects were in a supine position.  Section 
thickness was set at 10 mm, with 40 mm separating each section, based on previous 
work in our laboratory with slight modifications (18).  Each CT image was obtained 
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at 120 kVp with the scanning time set of 1 s at 40 mA.  A 48-cm field of view and a 
512 X 512 matrix were used to obtain a pixel resolution of 0.94 mm. CT scans were 
analyzed using the Medical Image Processing, Analysis, and Visualization (MIPAV) 
area assessment program (NIH, Bethesda). Briefly, IMF was distinguished from the 
subcutaneous adipose tissue by manual drawing of a line along the deep fascial plane 
surrounding the thigh muscles. IMF was then segmented into a separate image, in 
which the IMF, LDM and normal density muscle (NDM) were identified based on 
Hounsfield Units (HU) as follows:  IMF =  –190 to –30, LDM =  0 to 30, and NDM =  
31 to 100, as previously described (4, 19). Bone marrow adipose tissue area was 
excluded in the analyses.  The technician was blinded to subject identification, date of 
scan, and training status, for both baseline and after training scans.  Reproducibility of 
IMF, LDM and NDM was assessed by repeating the analysis of 12 CT scans 5 times 
performed on 5 separate days and showed a coefficient of variation of less than 5% 
for all three components.  
Strength testing 
      One-repetition maximum (1 RM) strength tests were assessed before and after the 
ST program using the same type of  air-powered knee-extension resistance machine 
(Keiser Sports/Health Equip. Co., Inc., Fresno, CA) as was used in training as 
described previously (12).  The same investigator conducted strength tests for each 
subject both before and after training using standardized procedures with consistency 
of seat adjustment, body position, and level of vocal encouragement. All subjects 
were positioned with a pelvis strap (seat belt) to minimize the involvement of other 
muscle groups. The 1 RM was achieved by gradually increasing the resistance after 
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each successful repetition from an estimated sub-maximal load until the maximal load 
was obtained.  A customized light system was used to assure that each attempted 
exercise trial achieved an appropriate range of knee extension. 
Training program 
     The training program consisted of unilateral (one-legged) training of the knee 
extensors of the right leg, three times per week, for ~ 10 weeks. Training was 
performed on a Keiser A-300 air powered leg extension machine.   The untrained 
control leg was kept in a relaxed position throughout the training program. Following 
the two familiarization training sessions previously described, the training consisted 
of five sets of knee extension exercise for those < 75 yrs of age and four sets for those 
≥ 75 yrs of age, as described by Delmonico et al.(20).  We did not have those ≥ 75 yrs 
perform the last set out of concern that performing 50 repetitions at near maximal 
effort for this age group might cause overtraining, which has been shown to result in a 
reduction in strength gains with training (21).  The protocol was designed to elicit 
near maximal effort on every repetition, while maintaining a relatively high training 
volume.    
Statistical analysis 
     ADRβ2 Gln27Glu and ADRα2b Glu12/Glu9 genotype distribution was evaluated 
for conformity with Hardy-Weinberg equilibrium using chi-square test with one 
degree of freedom. Changes in total body mass, FFM, body fat, percent body fat and 
1 RM were tested using paired t-test.  The influences of genotypes on the ST – 
induced effects on IMF, LDM and NDM were determined by analysis of covariance 
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(ANCOVA). The change in IMF, LDM and NDM was calculated by subtracting the 
difference between the changes (pre- to post-training) of the untrained leg from the 
change (pre- to post-training) of the trained leg. The ADRβ2 polymorphism was 
categorized as Glu27 carriers (Gln27Glu and Glu27Glu) and Glu27 noncarriers 
(Gln27Gln); The ADRα2b polymorphism was categorized as Glu9 carriers (Glu12 / 
Glu9 and  Glu9 / Glu9) and Glu9 noncarriers (Glu12 / Glu12). The initial linear model 
included the two genotype groups, sex and ethnicity as class variables, while age, 
change in body fat and baseline values were covaried for IMF, change in NDM were 
additionally covaried for LDM.  The model for NDM  covaried age and baseline 
values only.  The models also included selected two and three factor interactions.  
Non-significant sources of variation were deleted, one at a time, starting with the least 
significant higher order source. The significance was set as P < 0.05. All means were 
adjusted to the mean age (63 years), and weighted for gender-hormone replacement 
(7% female, hormone replacement, 46% female, non-replacement and 47% males), 
ethnicity (68% Caucasian and 32% African American) and genotype distributions 
(48% Glu27 carriers and 52% Glu27 noncarriers; 48% Glu9 carriers and 52% Glu9 
noncarriers). In addition, IMF means were also adjusted to change in body fat (-180 
gram) and corrected for baseline (trained minus untrained) IMF (-0.41 cm2); LDM 
means were also adjusted to change in body fat (-180 g) and change in NDM (19.34 
cm2), and corrected for baseline LDM (1.65 cm2); NDM means were corrected for 
baseline NDM (9.1 cm2).  
 





     The physical characteristics of subjects at baseline and after training for men (n = 
46) and women (n = 52) are shown in Table 1.  Men significantly increased their 
FFM and total body mass, whereas, women showed no significant change in FFM or 
total body mass in response to ST. There was no significant change in body fat or 
percent body fat in either men or women with ST. The 1-RM strength values 
increased by 28.4 % in men (+9.1 kg, P = 0.0001) and 27.8% in women (+5.2 kg, P = 
0.0001).  
Genotype 
     The genotype frequencies and sample sizes for the ADR alleles and genotypes are 
shown in Table 2. ADRα2b Glu12/Glu9 and ADRβ2 Gln27Glu allele frequencies were 
comparable to those reported previously (15), and fit the expectation of Hardy-
Weinberg equilibrium for each polymorphism (Gln27Glu, χ2 = 0.07, P = 0.97; 
Glu12/Glu9, χ2 = 0.36, P = 0.84). 
IMF, LDM and NDM 
     IMF was not significantly changed with ST in the whole group (0.35 ± 0.68, P = 
0.6114). There were significant training-induced reductions in IMF in the ADRβ2 
Glu27 carriers (-2.3 cm2, P = 0.028; Figure 1), but no significant change in IMF in 
Glu27 noncarriers. The training-induced reduction in IMF in the ADRα2b Glu9 
carriers approached significance (-1.9 cm2, P = 0.066; Figure 2), whereas ADRα2b 
Glu9 noncarriers did not experience significant changes in IMF with ST. The decrease 
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in IMF in the ADRβ2 Glu27 carriers with training was significantly different (-3.8 ± 
1.5, P = 0.014) from the non significant IMF change in the ADRβ2 Glu27 
noncarriers. The change in IMF responses to ST in ADRα2b Glu9 carriers was 
significantly different (-3.0 ± 1.4, P = 0.043) from the change in IMF in the ADRα2b 
Glu9 noncarriers.  
     Carriers of ADRβ2 Glu27 who also carry ADRα2b Glu9 alleles (Glu27 + / Glu9 +) 
showed a significant decrease in IMF with ST (-3.8 cm2, P = 0.018; Figure 3), while 
carriers of neither ADRβ2 Glu27 nor ADRα2b Glu9 alleles (Glu27 – / Glu9 –) showed 
a significant increase (+3.0 cm2, P = 0.046) in IMF. The change of IMF in Glu27 + / 
Glu9 + carriers was significantly different (-6.8 ± 2.3 cm2, P = 0.020) from Glu27 – / 
Glu9 – carriers. Other allelic combinations (ADRβ2 Glu27 + / ADRα2b Glu9 – or 
ADRβ2 Glu27 – / ADRα2b Glu9 +) showed no significant change in IMF with ST 
and there were no significant differences with other genotypes combined. 
     LDM was not significantly changed with ST (-1.35 ± 0.78, P = 0.09).  However, 
there was a significant ADRα2b genotype by change in NDM interaction effect on 
LDM response to ST (P = 0.0215). Thus, the effect of ADRα2b on LDM was 
dependent on size of the change in NDM with ST. The increase in NDM was 
consistent for all genotypes with ST (19.3 ± 2.2 cm2, P = 0.0001), when adjusted for 








     To our knowledge, this is the first study to examine the effects of ST and the 
influence of ADR genotypes on IMF and LDM. These results support our hypothesis 
that ADR genotypes influence the responses of IMF to ST, but do not support our 
hypothesis of a similar influence on LDM response to ST, or on a reduction of IMF 
and LDM with ST, independent of genotype.  The data demonstrate that ST reduces 
IMF in those who are ADRβ2 Glu27 carriers, but not in those who are Glu27 
noncarriers. In addition, Glu27 carriers who also carried ADRα2b Glu9 alleles, 
showed a significant decrease in IMF with ST, which was significantly different from 
those who carry neither ADRβ2 Glu27 alleles nor ADRα2b Glu9 alleles.   
     It has been reported that ST decreases both total and regional fat (22), including 
intra-abdominal fat (23).  Adrenergic receptors (ADR), especially ADRβ2, have been 
shown to play a major role in triglyceride lipolysis in adipose tissue and skeletal 
muscle (13).  Moreover, polymorphisms of the ADR gene have been associated with 
adipose tissue deposition and catabolism (24, 25).  In this context, ADR genotypes 
may influence exercise training-induced fat reductions.  For example, Phares et 
al.(15) reported a greater loss in total % fat and in trunk fat in ADRβ2 Glu27 carriers 
than in noncarriers, in response to aerobic exercise training. In addition, ADRα2b 
Glu9 noncarriers who also carried ADRβ2 Glu27 lost greater fat mass than 
noncarriers of either variant in their study. The results of the current study extend the 
results of Phares et al. (15) to ST by showing that ST-induced reductions in regional 
fat (IMF) is similarly influenced by the ADRβ2 Gln27Glu polymorphism, such that 
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Glu27 carriers respond to training by reducing IMF, whereas, noncarriers do not, in 
middle-aged and older adults.  
     Maintaining low levels of muscle fat is important for the elderly because of its 
association with metabolic disorders and functional disabilities (4-7). Nevertheless, it 
cannot be determined from these studies whether the magnitude of IMF loss with ST 
in the present study is enough to result in improved function or metabolic state.  
However, these results do suggest that reversing some of the age related muscle loss 
is not the only potential value of ST as an intervention for sarcopenia, at least for 
those of a specific genotype (e.g., carriers of ADRβ2 Glu27 allele alone or together 
with ADRα2b Glu9).   
     It is unclear why the ST program did not result in a significant reduction in IMF 
and LDM in the entire group, independent of genotype. There are several possible 
explanations. First, this is likely due to the significant increase in Glu27 – / Glu9 – 
carriers. Second, the energy expenditure of our training program was likely too low to 
account for a significant loss in regional or total body fat in the group as a whole.  
Only a single exercise that incorporates a single muscle group was used.  Although 
multiple sets of this exercise were performed, the total exercise time, when you 
exclude rest periods, was less than 5 minutes, which accounts for a low energy 
expenditure training protocol.  Third, this type of heavy resistance, short duration 
exercise uses anaerobic metabolism as the primary energy pathways (26). Although 
increased intramuscular lipid oxidation has been observed in electrically induced 
contraction of isolated skeletal muscle (27) and after 5 hours of continuous knee 
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extensor exercise (28), these studies used a very different experimental stimulus than 
was used in the present investigation. 
     However, despite no significant change in total body fat and the use of low energy 
expenditure and a primarily anaerobic exercise regime, we found significant ST - 
induced reductions in mid-thigh IMF in those subjects who either carry the ADRβ2 
Glu27 allele alone or both ADRβ2 Glu27 and ADRα2b Glu9 alleles. In this regard, 
Green et al (29) reported that the presence of the Glu27 allele is protective against the 
agonist – induced decreases in ADRβ2 expression, although other studies claimed the 
opposite for  receptor functions (30). Based on the Green et al (29) study, we 
postulated that Glu27 allele carriers may have more ADRβ2 receptors than Glu27 
allele noncarriers in response to ST-induced catecholamine stimulation, thereby 
resulting in more hydrolysis of triglyceride in IMF. Small et al (31) reported that the 
presence of Glu9 resulted in a decreased inhibition of adenyle cyclase (AC) by 
ADRα2b. Thus, we postulated that the presence of Glu9 favors lipolysis stimulated by 
ADRβ2, resulting in a greater likelihood of significant reductions in IMF in those  
who carry both Glu27 and Glu9 alleles.   Nevertheless, lipolysis is not a perfect 
predictor of fat loss because FFAs released from lipolysis can be reesterified back to 
triglyceride if not oxidized by muscle.  Thus, fatty acid oxidation becomes an 
important part of the explanation for exercise training-induced fat loss, which will 
require further study.   
     To control for biological, seasonal and methodological variations, investigators 
have used a no exercise control group (9). However, a no exercise control group 
cannot control for genetic differences between the two groups, attention effects due to 
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the training group receiving more attention than the control group, or the many 
differences resulting from group heterogeneity.  Therefore, we have recommended 
unilateral limb training, using the untrained limb as a control, to isolate the 
independent effects of ST (32).          
     However, there were limitations of the present study. First, although our sample 
size is considered relatively large when compared to previously published ST studies, 
it is small for genotype comparisons. Therefore, we limited our comparisons to Glu27 
carriers vs Glu27 allele noncarriers, instead of comparing all three genotype groups, 
to achieve our 80% criterion for statistical power. Second, the age range of subjects in 
this study was quite large (50 to 83 years).  However, we did covary for age in our 
analysis to account for this heterogeneous age group.  Third, training was restricted to 
the quadriceps muscle group, yet a portion of the fat measured fell into the adjoining 
hamstrings muscle group.  In addition, it has been estimated that ~50% of the FFA 
oxidized during exercise comes from the general circulation (33, 34). Therefore, the 
reduction of thigh IMF with ST in the ADRβ2 Glu27 carriers could possibly be 
accompanied by reductions of fat in other regions, not measured in this study.  It is 
likely, however, that other regions did not experience significant fat reductions, given 
that there was no significant reduction in total body fat, subjects were constantly 
reminded not to change their usual caloric intake, were weighed weekly to assure 
compliance, and the caloric expenditure of the training protocol was low.  Finally, 
although the inclusion of seven women who were taking hormone replacement 
medication in this study should be considered a limitation, we included these women 
as a separate group in the statistical analysis and there were no significant differences 
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in IMF response to ST between the seven women who were taking medication and 
those who were not.    
     In conclusion, this is the first study to report that ADR genotype can influence the 
effects of ST on intermuscular fat in middle-aged and older adults. The data indicate 
that those who carry the ADRβ2 Glu27 allele alone or with ADRα2b Glu9 allele 
experience a reduction in intermuscular fat as a result of strength training. The results 
of the present study also provide support for new hypotheses to investigate other gene 
polymorphisms, such as ADRβ3, larger scale investigations, and to examine 
functional or metabolic changes associated with the ST-induced reductions in 
intermuscular fat.   
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Table1.    Physical Characteristics at Baseline and After Strength Training (ST)  
 
 Baseline After ST  
Men (n = 46)   
      Age (years)             64.4 ± 1.2  
      Height (cm)           173.8 ± 1.0 ---- 
      Total body mass (kg)             84.0 ± 1.8      84.5 ± 1.9* 
      Body fat (kg)             23.4 ± 1.0             23.3 ± 1.0 
      Percent body fat (%)             27.4 ± 0.8             27.2 ± 0.7 
      FFM (kg)             60.6 ± 1.1             61.2 ± 1.1** 
     1-RM (Kg) ‡             32.4 ± 1.2             41.5 ± 1.6** 
Women (n = 52)   
       Age (years)             62.7 ± 1.2  
       Height (cm)           162.5 ± 0.8 ---- 
       Total body mass(kg)             73.2 ± 1.7   73.3 ± 1.8 
       Body fat (kg)             28.9 ± 1.1   28.7 ± 1.1 
       Percent body fat (%)             38.8 ± 0.7   38.5 ± 0.7 
       FFM (kg)             44.3 ± 0.7   44.6 ± 0.8 
      1-RM (Kg) ‡             18.7 ± 1.0               23.9 ± 1.0** 
   Values are mean ± standard error. FFM: fat free mass  
   1 RM: one repetition maximum 
* P < 0.05, * * P < 0.01 
‡ There were two women and one man who had missing 1 RM data. 
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Table 2. Adrenergic Receptor (ADR) Gene Polymorphisms: Allele and Genotype 
Frequencies and Sample Sizes. 
 ADR gene polymorphisms 
alleles and genotypes 
Frequency Sample Size 
ADRα2b Glu12 0.73 - 
         ADRα2b Glu9 0.27 - 
        ADRα2b Glu12/Glu12 0.52 51 
                        Glu12/Glu9 0.42 41 
                       Glu9/Glu9 0.06 6 
ADRβ2  Gln27 0.72 - 
ADRβ2  Glu27 0.28 - 
     ADRβ2   Gln/Gln 0.52 51 
                     Gln/Glu 0.41 40 


























Figure 1.  Change of intermuscular fat (IMF) with ST in adrenergic receptor (ADR) 
β2 Glu27 carriers and noncarriers.  P values connecting two bars represent tests of 
differences between genotypes and p values associated with a single bar represents 
change due to training effects in the designated genotype group.  All other differences 
and changes were non significant.  .   
Figure 2.  Change of intermuscular fat (IMF) with ST in adrenergic receptor (ADR) 
α2b Glu9 carriers and noncarriers. P values connecting two bars represent tests of 
differences between genotype groups and p values associated with a single bar 
represent changes due to training effects in the designated genotype group.  All other 
differences and changes were non significant.   
Figure 3.  Change of intermuscular fat (IMF) with ST in carriers of adrenergic 
receptor (ADR) β2 Gln27Glu and ADRα2b Glu12 / Glu9 polymorphisms combined.  P 
values connecting two bars represent tests of differences between designated 
genotype groups and p values associated with a single bar represent changes due to 
training effects for the designated genotype group.  All other differences and changes 
were non significant.     






































Glu27 carriers  (n = 47)                          Glu27 noncarriers  (n =51)
* P = 0.028   
 † P = 0.014
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Change of IMF in carriers of ADRβ2 and ADRα2b genotypes combined 
 
 






















   * P = 0.018
 Glu27+ /Glu9 +  Glu27- /Glu9 + Glu27+ /Glu9 - Glu27- /Glu9 -
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Research Hypotheses  
1. IMF and LDM will be reduced after 10 weeks of ST, independent of 
genotypes, gender and ethnicity. 
2. ADRβ2 Glu27 allele carriers will lose more IMF or LDM than noncarriers in 
response to ST 
3. ADRα2b Glu9 allele carriers will lose less IMF or LDM than noncarriers in 
response to ST. 
Delimitations 
1. The scope of this study will be delimited to 98 men and women between the 
ages of 50 and 81 yrs who volunteer as study participants. 
2. Participation in the study will be limited to healthy participants free of 
musculoskeletal or cardiovascular disease. 
3. Based on previous research, subjects will be divided into three groups in 
determining the effect of ADRβ2 and ADRα2b, respectively. The groupings 
will be based on homo and heterozygosity for the ADRβ2 Gln27Glu or 
ADRα2b Glu12/Glu9 polymorphism. 
Limitations 
1. The participants will not be randomly selected from the general population, 
but volunteers. Therefore, the results of this study cannot be generalized to 
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individuals who do not possess characteristics such as age, body size, physical 
activity, etc. similar to those of subjects in the study. 
2. Many factors related to health and lifestyle such as dietary habits, physical 
activity habits, medication regimens, and medical conditions will be reported 
by subjects. Because the accuracy of these reports cannot be verified, it is 
possible the results of this study could be adversely affected if inaccurate self-
reports occur. 
3. It will not be possible to verify compliance of factors that are not being self 
reported, but are part of what subjects are asked to do outside of training 
during the study period. (e.g. maintain diet and activity patterns and not 
change their medications). 
4. Genotypes other ADRβ2 Gln27Glu and ADRα2b Glu12/Glu9 polymorphisms 
will not be assessed in the proposed study. It is possible that the ADR 
polymorphism effects are present only in the presence of a specific, but 
unknown, genetic background. 
5. Polymorphisms in the regions flanking the ADRβ2 and ADRα2b genes will 
not be identified or assessed in the genomic material for this study. It is 
therefore possible that any reported genotype effect is due to linkage 
disequilibrium between the ADRβ2 Gln27Glu or Glu12/Glu9 polymorphism 





Computed tomography (CT): A technique for assessing normal muscle size based 
on the examination of axial scans of the thigh. Visual images are created from the 
measurement of the intensity of X-rays and analyzed to measure cross-sectional area. 
The images are based on the attention of X-rays as they pass through the body. 
Attenuation scores are measured in Hounsfield Units, which depend on the level of 
absorption of emitted x-ray beams, -1000 air to +1000 bone. Skeletal muscle is 
typically 0 to 100 and adipose tissue is usually -190 to -30. 
Dual-energy x-ray absorptiometry (DXA): A technique for assessing whole and 
regional body composition that considers the body to be composed of three 
compartments: bone mineral mass, soft mass and lean tissue. Tissue amounts are 
based on the attenuation of x-rays as they pass through the body. 
5-RM: Refers to the maximum amount of resistance an individual can move through 
a complete range of motion only five times 
Adrenergic receptors (ADRs): a class of G-protein coupled receptors that is the 
target of catecholamines (Epinephrine or Norepinephrine) and activated by these, 
including nine subtypes: α1A, α1B, α1D; α2A, α2B, α2C; β1, β2 and β3. 
ADRB2 gene: The gene encoding ADRβ2 receptor, located on chromosome 5(5q31-
q32), spans ~22 kbp and contains 1 exon. 
ADRA2B gene: The gene encoding ADRα2b receptor, located on chromosome 
2(2p13-q13), spans ~21 kbp and contains 1 exon. 
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Gln27Glu polymorphism (ADRβ2 gene): Results from a C to G transition at 
position 79, which causes a change in the 27 residue from Glutamine to Glutamic 
acid at amino terminus. Genbank accession number Y00106. 
Glu12/Glu9 polymorphism (ADRα2b gene): Results from the deletion of three 
Glutamic acids from a Glutamic acid repeat element (Glu×12, amino acids 297-309) 
present in the third intracellular loop of the receptor. 
Intermuscular fat (IMF): Fat interspersed within muscle, visible within the muscle 
area in CT images and can be distinguished with HU of -30 t0 -190 
Low density muscle (LDM): Muscle with attenuation lower than 30HU but higher 
than 0 HU, usually due to increased fat deposit within myocytes or around muscle 
bundles. 
Normal density muscle (NDM): Muscle with attenuation higher than 30 HU until 
100 HU. 
Sarcopenia: A condition characterized by the age-associated loss of muscle size and 
strength, accompanied by increased fat infiltration. This typically leads to or 
exacerbates ailments such as osteoporosis and loss of functional independence. 
Sedentary:  A description for individuals who are not physically active. In the 
proposed study this term describes individuals who, on average, have exercised 
aerobically for less than 20 minutes per day less than 2 times per week and have not 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































APPENDIX C: GENOTYPES 
 





   
BETA GC CC
Sub# 055 054 053 051 049 048 047 046 045 044 041 040 039 038 034 043 033 032 031 030 028 027 026












































































APPENDIX E: LITERATURE REVIEW 
 
     The following review of literature provides background information on sarcopenia 
and includes a review on fat infiltration, strength training (ST) as an intervention for 
sarcopenia, and the role of genetics in influencing ST adaptations.  This review will 
focus on the following topics: 1) Sarcopenia: muscle loss and fat infiltration, 2) 
Interventions for sarcopenia 3) Genetics of ST adaptation, and 4) Influences of ADR 
polymorphisms on lipid metabolism  
Sarcopenia: muscle loss and fat infiltration 
 
      Sarcopenia is defined as the loss of muscle mass with aging, which subsequently 
affects muscle strength, power, and functional abilities (1, 35).  These losses are 
associated with multiple adverse health outcomes in the elderly, such as frailty, 
increased risks of falls and fracture, osteoporosis, glucose intolerance and eventually, 
the loss of independence (36-38). Because sarcopenia is considered a multifactorial 
condition that to some extent occurs as a natural part of aging, no single factor has 
been identified that explains entirely the aging-related loss of muscle size or function.  
However, there is significant inter-individual variability in sarcopenia.  Some of the 
major factors that appear to contribute to sarcopenia are decreases in motor neurons, 
anabolic hormones (sex steroids and growth hormone), protein consumption, and a 
rise in catabolic stimuli, such as cortisol and cytokines (e.g. interleukin-6, 1 and 
tumor necrosis factor - α) (39, 40).     
     Baumgartner et al. (41) defined sarcopenia as stature-adjusted appendicular 
skeletal muscle (SM) mass (i.e., SM mass / height 2) more than 2 standard deviations 
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(SD) below the mean of a young reference population. With this definition, among 
808 subjects up to 30% of women and 50% of men over age 80 years were classified 
as sarcopenic in the New Mexico Elder Health Survey (41). Janssen et al. (42) studied 
the older men (n = 2224) and women (n = 2278) from the Third National Health and 
Nutrition Examination Survey with SM mass percent of body weight for defining 
sarcopenia as class I (-1 SD to -2 SD) and class II (> -2SD). The prevalence of class I 
sarcopenia is 59% and 45% in older women and in older men, respectively, and the 
prevalence of class II sarcopenia is 10% for older women and 9% for older men.  
Moreover, the recent data quantifying appendicular skeletal muscle mass in ~ 200 
women aged 64 – 93 and ~ 140 men aged 64 – 92 yr, found that the overall 
prevalence of sarcopenia was ~ 23% in women and ~ 27% in men and up to 45% in 
those over the age of 80 (43).  These results indicate that sarcopenia affects a large 
number of elderly populations.  
     Numerous studies have shown that SM mass or size is smaller in older people in 
comparison to younger people as measured by various methods (44-54).  The cross-
sectional data from Janssen et al. (48) demonstrated that muscle mass remains 
relatively constant until the 40s, and then starts to decline after 45 yrs. Estimations 
based on the longitudinal studies (55-57) showed that SM mass decreases at a rate of 
6% per year and that ~  one quarter of SM mass is lost by 85 years of age. Muscle 
loss is mostly observed as decreased cross-sectional area (CSA) and decreased 
number of muscle fibers, especially type 2 fibers. Young et al. (47) found that 
quadriceps CSA was 23% and 33% smaller in elderly men and women, respectively, 
than in younger subjects.  These data are supported by the later work of Hakkinen 
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(58) who found a 27% lower mid-thigh CSA in older women when compared to 
younger women. Moreover, the loss of muscle mass was greater in the lower 
extremities.  The initial amount of muscle mass and the rate of muscle loss with aging 
determine the progression of sarcopenia (59).  There are few studies examining the 
effect of gender and ethnicity on sarcopenia. Several cross-sectional studies found 
that there was more age-associated SM loss in men than in women (48, 53, 60). In 
regard to the effect of race, one study found greater age-associated losses in SM 
among African–Americans than Caucasians (53), whereas another study supported 
the opposite finding (61).  
     Age –associated loss of muscle strength and power is one important component of 
sarcopenia. Muscle volume and strength reach a peak between 40 and 50 yrs of age 
and remain relatively stable until the 60s.  Beginning at ~ age 60, muscle strength will 
begin to decline at approximately 12 – 14% per decade (54).  This is equivalent to a 
loss of muscle function of ~ 40% by the 80s and often leads to disability and 
morbidity and is even associated with increased mortality (62, 63).  Loss of muscle 
mass plays an important role in the reduction of muscle strength, while other factors 
such as SM composition (5), and contractile protein level also contributes to the 
declining muscle strength with aging (52). The loss of muscle mass and strength will 
affect functional abilities, possibly leading to functional impairments and disabilities 
with aging. Baumgartner et al. (41) reported that sarcopenic men and women have a 3 
to 4 times higher odds ratio of disability than older people with normal muscle mass. 
Janssen et al. (42) reported a two to three-fold greater likelihood of disabilities in 
older men and women with sarcopenia compared to those without sarcopenia. Both 
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studies adjusted for age, race, obesity, health behaviors and comorbidity. Thus, 
sarcopenia is strongly associated with functional limitations and disabilities in the 
elderly.   Furthermore, it has been reported that adjusted arm muscle area is a better 
predictor of mortality than body mass index (BMI), which is often used as a predictor 
of mortality in older adults (63).    
     Recently, the components of sarcopenia have been extended to include increased 
fat infiltration into skeletal muscle corresponding to muscle mass and strength loss. 
Significant changes in body composition with aging, such as increased body fat and 
decreased muscle mass have been observed in several studies (53, 64, 65). For 
example, it was estimated that adults aged 30 to 60 yrs gained ~ one pound of body 
fat and lost half a pound of muscle mass on average every year. That would be 
equivalent to a gain of 30 pounds of fat and a loss of 15 pounds of muscle. This 
increase in fat mass often masked a concomitant decrease in SM, because of a relative 
constancy in body weight in the elderly.  The cross-sectional data (66) demonstrated 
that healthy men 25 yrs of age have ~ 20% body fat, while men 55 yrs of age have ~ 
30 % body fat.  The hypothesis that aging is associated with increases in fat and 
connective tissues is supported by several studies (67, 68). More recent longitudinal 
(2) and cross sectional studies (69) showed that not only is total body fat increases 
associated with aging, but regional fat infiltration into muscle increases with age, or 
at least associated with aging.   
     Fat infiltrates into SM through either depositing extra amounts of triglyceride (TG) 
near the mitochondria within myocytes, i.e intramyocellular TG (imTG) or around 
muscle fibers or bundles, i.e extramyocellular TG.  Magnetic resonance spectroscopy 
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(MRS) is the only non invasive method that can distinguish imTG from 
extramyocellular TG, but it is expensive and time consuming. Other methods used to 
measure SM lipid content include muscle biopsy and computer tomography (CT). 
Biopsies have several limitations, such as being an invasive technique and poor 
reliability (70). CT measured tissue composition is based on the intensity value 
(Hounsfield Unit, HU), with advantages such as being noninvasive, inexpensive, and 
high accuracy.  Kelley et al. (19) found muscle attenuation in CT was lower  in obese 
subjects than in lean subjects, due to the high content of imTG and extramyocellular 
TG.  The low density muscle (LDM) was defined by Goodpaster et al. (71) as muscle 
with attenuation of 0 to ~ 30 (Housfield Unit, HU), comparing to normal density 
muscle (NDM) having an attenuation of ~ 30 to ~ 100 HU. Increasing amount of fat 
interspersed between muscle groups, i.e. intermuscular fat (IMF) is another form of 
fat infiltration. IMF can be easily distinguished from SM and LDM due to a much 
smaller density of -190 to -30 HU in CT imaging. 
     A number of studies (2, 46, 68, 69, 72) have shown that LDM and IMF increase 
with aging. Song et al. (2) followed 26 African American (AA) women for two years 
and observed increases in visceral fat and IMF corresponding with reductions in SM. 
Ryan et al. (69) investigated 72 women with wide range of body fat in a cross-
sectional study and found that mid-thigh LDM significantly correlates with age. 
     LDM and thigh IMF may be linked to age-related insulin resistance in muscle. 
Insulin resistance is a main risk factor for type 2 diabetes and cardiovascular diseases, 
which are common in the elderly.  Goodpaster et al. (73) examined 54 healthy 
sedentary men and women and found that muscle attenuation contributed to insulin 
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sensitivity, independent of visceral and subcutaneous abdominal fat. In obese 
subjects, muscle attenuation is the strongest single correlate of insulin resistance. 
Moreover, Cuff et al. (10) reported that a reduction in LDM induced by ST and 
aerobic training (AT) combined, independently resulted in an improved glucose 
disposal rate. Goodpaster et al. (4) compared mid-thigh IMF, subcutaneous fat and 
muscle attenuation among obese subjects with type 2 diabetes, obese and lean 
subjects. IMF was highest in obese subjects with diabetes and a strong predictor of 
insulin resistance, although it only accounted for 3% of thigh fat mass. Subcutaneous 
adipose tissue, however, did not correlate with insulin resistance. Goodpaster et al. (3) 
then further identified this association in 2,964 elderly men and women (aged 73.6 
yrs) by showing that both elderly men and women accumulated an increasing amount 
of IMF from the status of normal glucose, glucose impaired to the status of type 2 
Diabetes. Moreover, the higher amount of IMF and abdominal VAT was associated 
with higher fasting insulin in normal weight men and women.  However, Janssen et 
al. (11) did not observe any metabolic improvements resulting from the reduction of 
IMF by energy restrictive diet combined with either ST or AT.  
     In addition to metabolic disorders, LDM was recently reported to be associated 
with loss of muscle strength (5), and with the decline in leg function and with 
mobility limitation in the elderly (6).  Goodpaster et al. (5) examined nearly 3000 
older subjects from the Health ABC study and found that mid-thigh muscle 
attenuation was lowest in the eldest men and women; lower muscle density was 
associated with lower specific force production (r=0.26, P<0.01), which was 
independent from mid-thigh muscle mass and adipose tissue. Visser et al. (6) studied 
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subjects with similar characteristics of those in the Health ABC study and found that 
the reduced muscle attenuation was associated with a poorer lower leg performance 
(measured by a 6-meter walk and repeated chair stands), independent of total body fat 
and muscle area.  Then, Visser et al. (7) followed up these subjects for 2.5 years. 
Mobility limitations were developed in 22.3% of the men and in 31.8% of the 
women. The hazard ratio of developing mobility limitations in subjects who had the 
lowest muscle attenuation was 2.16 times higher than those who had the highest 
muscle attenuation. These findings indicate that muscle attenuation (the reflection of 
muscle lipid content), together with muscle strength and muscle mass, is a predictor 
of incident mobility limitations in well-functioning older persons.  
     The mechanisms under which fat infiltration increases with aging are not known. 
TG is formed by esterifying free fatty acids to glycerol (lipogenesis). To use fat as a 
fuel, TG must first be hydrolyzed (lipolysis) and the resultant fatty acids are then 
transported by blood flow to skeletal muscle mitochondria for oxidation. The 
regulation of adipose tissue lipolytic activity is involved in the release of 
catecholamines (norepinephrine and epinephrine), binding to adrenergic receptors 
(ADRs) and activating hormone-sensitive lipase. At rest, the amount of fatty acids 
released from adipose tissue typically exceeds the amount oxidized, while mid or 
moderate–intensity exercise is associated with a 5-10 fold increase in fat oxidation 
above resting amounts. Some studies (74, 75) found a decreased lipid oxidation rate 
within SM in a resting stage in the older people. Therefore, it is possible that changes 
in SM occur as a natural aging process. Other factors possibly contribute to the 
increased fat infiltration into SM with aging. For example, high saturated fat intake in 
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the older individuals and leptin resistance possibly increase lipogenesis (76). 
Moreover, a decreased level of social and physical activity with advancing age may 
lead to decreased lipolysis and oxidation in the elderly.  
     Genetic determinants may also influence fat infiltration in the aging muscle. The 
ADR genes are of particular importance for the fat deposition and distribution 
because of the central role of catecholamines in the regulation of lipolysis and energy 
expenditure. For example, Large et al. (77) found that G allele carriers of ADRβ2 C-
27G polymorphism tend to possess more fat than noncarriers. ADRα2b Glu9/Glu9 
carriers have decreased basal metabolic rates (78).  For this reason, those who have 
specific genetic backgrounds may be prone to the accumulation of more fat in skeletal 
muscle with aging. The influence of ADR gene polymorphisms on lipid metabolism 
will be discussed in detail in the latter part of this review.  
Interventions for Sarcopenia 
 
     As a result of the increased prevalence of sarcopenia, the total health care costs 
and detrimental physical consequences that follow, it is imperative from a public 
health perspective to find a safe and effective method to increase muscle strength and 
mass in the elderly.  Hormonal interventions, nutritional supplements and strength 
training have been investigated to determine their effectiveness for slowing or 
reversing sarcopenia.  
      Hormonal Interventions.  Based on evidence that age-related decline in growth 
hormone (GH) and insulin-like growth hormone-1 (IGF-1) may contribute to the 
development of sarcopenia (79-81), several studies (82-85) have addressed the 
question of whether age–associated muscle loss can be reversed through GH 
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supplements. Rudman et al. (82) observed a 8.8% increase in lean body mass 
resulting from 6 months of subcutaneous GH injections in 21 healthy men aged 61 to 
81 yrs. The effect of GH supplements on muscle strength was not tested in this study. 
When the trial period was elongated to 12 month in another study (83) conducted by 
the same group, a resulting 6% increase in lean body mass was accompanied by 
substantial frequency of adverse side effects such as carpal tunnel syndrome, 
gynaecomastia and hyperglycaemia. All participants in these two studies had low 
serum IGF-1 levels before supplementation, but these levels were restored within the 
normal range after GH supplementation. Moreover, Papadakis et al. (84) tested the 
knee and handgrip strength after GH administration, but did not see any differences 
between supplement group and control group, although the lean body mass was 
increased with GH administration. The incidence of side effects in the GH group was 
consistently higher than in the control group. Chu et al. (85) reported that 4 weeks of 
low dose GH administration plus dietary interventions increased lean body mass, 
which was subsequently associated with a faster walking speed. In all of these 
studies, incidence of adverse effects in the GH group was significantly higher than in 
the placebo group. Moreover, the administration of GH in critically ill older subjects 
may result in increased mortality (86). Thus, clinical utility of GH supplement is 
limited because of little effect on muscle strength and high incidence of adverse 
effects, as well as the high cost. The other two alternate strategies of enhancing 
GH/IGF-1 pathway are administration of growth hormone releasing hormone 
(GHRH) (87, 88) and the complex of IGF-1 with its major circulating binding protein 
(89). More investigation is needed to determine their effectiveness (90).  
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     Cross-sectional (91-93) and longitudinal studies (94, 95) have shown that 
testosterone level declines with age. In a Boston area aging study, at least 4% of those 
between 40 and 70 years of age had severe androgen deficiency, without any 
symptoms (92). Data from the Baltimore Longitudinal Study of Aging (BLSA) (96), 
demonstrated that testosterone level is not only lower in the elderly, but also begins to 
decline progressively with aging, starting in the 30s.  Lower testosterone 
concentration has been linked to decreased FFM and reduced muscle strength in both 
animals (97) and human (98). Based on the rational that anabolic testosterone may 
increase on muscle mass, therefore leading to improved functional abilities, a number 
of studies have tested the effect of intramuscular administration of testosterone on 
age-associated loss of muscle mass and strength (99, 100). The physiological dose of 
testosterone administation in elderly hypogonadal men resulted in increases in muscle 
mass (101-105), strength (99, 104, 106, 107), functional abilities (99), and a decrease 
in body fat (103-105, 108).  In contrast, the physiological dose supplement of 
testosterone has no effect on muscle strength in eugonadal individuals, although 
muscle mass is increased. The supraphysiologic dose of testosterone, however, 
induced increases in muscle mass and muscle strength in elderly eugonadal men (109, 
110). The adverse effects of testosterone administration can be relatively severe.  For 
example, Tenover et al. (101) reported elevated level of prostate specific antigen and 
hematocrit levels. Other potential adverse effects include prostate carcinoma and 
provocation of aggressive behaviors.  
      Some studies tested the effect of dehydroepiandrosterone (DHEA), which is the 
precursor of adrenal sex steroids on muscle mass and strength. However, the results 
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are controversial since some studies found significant increases in muscle mass and 
strength in men, but not in women (111), whereas, other studies did not observe any 
effects on muscle mass or strength in men or women (112, 113). Thus, further studies 
are needed before any definitive conclusions can be reached on the efficacy of DHEA 
as an intervention for sarcopenia. 
     Body composition was found to change with normal menopausal transition. For 
example, Poehlman et al.(114) observed a 3 kg loss of lean body mass, but 2.5 kg 
accumulation of fat mass in 35 women experienced menopause over years, compared 
to age-matched group who remained premenopausal This provides a rational for 
estrogen replacement to reverse muscle mass loss in elderly women. However, the 
information on this effect is limited and the available results fail to support an effect 
of estrogen supplement on sarcopenia. For example, Baumgartner et al. (115) 
compared a group of elderly women who received estrogen supplements with a 
control group of similar age, and found that estrogen supplement therapy is not 
associated with either increases in muscle mass or strength. Although these results 
were supported by other studies (116, 117), the data from Sorensen et al. (118) 
showed an association between estrogen supplement therapy and a significant 
increase in lean body mass and decrease in total fat mass.  In conclusion, the effects 
of hormonal (GH, testosterone and estrogen) interventions on sarcopenia are not 
optimal and have adverse effects on the health status of the elderly.  
      Nutritional Supplements.  The loss of muscle mass must be a result of net muscle 
protein breakdown; i. e. muscle protein breakdown exceeds muscle synthesis over a 
particular period of time. Thus, inadequate protein intake and unbalanced protein 
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metabolism may contribute to the development of sarcopenia.  Food and energy 
intake appeared to be reduced in older adults (119). Numerous data have indicated 
that inadequate protein intake is associated with muscle atrophy in the elderly (120).  
All of this suggests that modifications in nutritional habits, especially protein and 
amino acid intake, may help to counteract the age-associated loss of muscle mass.  
     Whether protein intake requirement is modified during aging remains 
questionable. Some studies support recommending higher protein intakes with 
advanced age due to age-related losses of muscle mass, functional abilities and 
declines in protein intake (121, 122), whereas other studies (120, 123) found minimal 
change with age in protein needs and utilization.  For example, Campbell et al. (122) 
placed 10 healthy older men and women on eucaloric diet with Recommended 
Dietary Allowance (RDA) protein (0.8 g / kg / day) for 14 weeks. The mid-thigh 
cross sectional area significantly decreased and the protein excretion declined, 
suggesting adaptation to low protein intake. These data suggest that the protein RDA 
for the elderly may be set too low to preserve muscle mass in these older people. 
However, more studies are needed to define new RDA for the elderly because of the 
mixed results from previous studies. Although the available information is 
insufficient to make a firm recommendation on an increase in protein intake of older 
people, it is clear that it is important to maintain adequate protein intake in the elderly 
to counter the initial development of sarcopenia. Castaneda et al (124, 125) clearly 
demonstrated that low protein diet (56% RDA)  for 10 weeks resulted in significant 
loss of muscle mass and functions in elderly women, while elderly women who 
consumed 115% RDA protein successfully maintained the muscle mass and strength.  
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     Essential amino acids, particularly branched amino acids like leucine, can induce 
stimuli in muscle protein synthesis while nonessential amino acids fail to induce even 
at a very high dose in both young and older people (126-128). Pannemans et al. (129) 
reported that protein deriving from vegetables which contains incomplete essential 
amino acids caused less net protein synthesis than protein deriving from animals in 
the elderly women. The stimulation of protein synthesis by leucine-rich meal was 
seen in old rats (130, 131), and this effect lasted at least 10 days, suggesting that a 
long-term utilization of leucine may prevent the muscle wasting with age. Clarkson et 
al. (132, 133) studied the effect of creatine on muscle mass, muscle strength and 
muscle performance.  A 30 day oral creatine supplement results in only small 
increases in muscle performance in the men over the age of 60 years. There are no 
significant differences in fat free mass and muscle strength between creatine 
supplement and creatine non-supplement group.  
     The protein digestion rate influences protein retention. For example, Boirie et al. 
(134) found that proteins with a fast absorption rate resulted in high plasma amino 
acid levels, which was associated with an increased whole-body protein synthesis and 
oxidation, and no change in protein breakdown; whereas, the protein with slow 
absorption rate slightly increased protein synthesis and oxidation. When the 
discrepancy in amino acids composition is considered, proteins with good absorption 
rate still have better postprandial utilities. Therefore, a quick and easily digested 
protein mixture may help increase protein retention in the elderly. In addition, Volpi 
et al. (135) showed that the different way of amino acids are administered 
(intravenous or oral) did not result in different plasma amino acids level.   
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     Despite these findings, no apparent beneficial effect has been observed in prior 
attempts to counter sarcopenia (36, 136, 137) . In a randomized, placebo control trial, 
Fiatarone et al. (36) found that nutritional supplement alone failed to increase either 
muscle mass or muscle strength in the frail elderly. Moreover, the addition of 
nutritional supplements to ST did not increase muscle mass and muscle strength 
above the level achieved by ST alone (136, 137). Campbell et al. (136) found 
efficiency of retention and protein utilization during ST was higher in older subjects 
who consumed 0.8g vs 1.6g protein/kg/day of dietary protein, but the two different 
diet groups did not experience different muscle hypertrophy.  Campbell’s group (138) 
also compared the effect of meat containing diet with lactoovovegetarian on muscle 
mass changes under ST, and no difference was observed in the two groups regarding 
muscle mass and muscle size. However, Meredith et al (139) reported that a group 
taking energy-protein supplement (560 calorie surplus per day) gained significantly 
higher muscle mass without alterations in strength gained with ST than the group that 
had the same ST program, but without supplements.  Thus, it appears that adequate 
energy intake rather than high protein intake has apparent additive effects on ST.  
      In addition, Volpi et al. (128, 140) suggested that makeup of nutritional 
supplements could affect the influence of supplements by showing that amino acids 
mixture actually stimulated muscle protein anabolism in older subjects. Those studies 
mentioned previously in this regard (36, 136, 137), all assigned subjects to a balanced 
meal consisting of protein, fat and carbohydrate. Volpi et al. (141) suggested that the 
addition of glucose may blunt the anabolic response of muscle to the stimulation of 
amino acid in the older adults. More longitudinal studies are needed to confirm 
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relationships between optimizing protein intake and preventing age-associated muscle 
loss. 
     The vitamin B6, magnesium and potassium were shown to relate to SM function 
in the elderly (142). However, reports on beneficial effects of multi-nutrient 
supplements on declining muscle mass and strength in the elderly could not be found. 
      Strength training.  Because of the prevalence of sarcopenia and its adverse 
influences on the elderly,   interventions designed for the prevention and treatment of 
sarcopenia should positively affect muscle mass, strength, and power without adverse 
side effects. For this reason, ST, rather than hormonal and nutritional interventions, 
should be the intervention of choice for sarcopenia, due to the substantial evidence for 
its efficacy within a very short time frame and for its safety (8, 143-145).  Numerous 
investigations have shown the efficacy of ST to increase muscle mass and strength in 
older adults ranging from 50-98 years of age (143, 146-149). Additionally, the muscle 
adaptations in the elderly with ST have been shown to improve functional abilities 
(150).   
     Earlier work by Frontera et al (147) found that ST in older men leads to increased 
strength of the quadriceps with an increase in muscle fiber size.  Since this data was 
published, numerous other investigations have been reported (32, 151-153) showing 
that muscle strength increases ~ 20 to 40% in response to ST in the elderly.  This 
large range is at least partially due to study design differences.  Problems arise when 
attempting to make comparisons between different ST studies, especially with 
different outcomes.  First, studies vary greatly with regard to muscle group studied 
(e.g. upper body vs. lower body) as well as the volume (i.e. repetitions x sets) and 
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intensity (% of strength) used as an intervention.  Furthermore, between-study 
comparisons are also problematic due to differences in the session frequency and 
duration of training interventions.  Some report that improvements can be seen in as 
few as one session per week (154), while others used as many as seven sessions per 
week (155).  The duration of ST interventions also vary considerably, with some 
lasting as little as four weeks (155) to almost two years (156), but most last between 8 
– 12 weeks (157).  Perhaps most importantly, the problem with comparing studies on 
the effects of ST interventions in older adults is the differences in subjects among the 
various studies. These variations include sex differences between groups, with some 
studies examining one sex, while other studies include both men and women (157). 
The ages of the study subjects can also vary significantly, with older subjects 
included ranging from those in their 50s to their 90s.  In addition, subjects vary based 
on medical condition, medications, previous exercise experience, socioeconomic 
status, racial and genetic backgrounds.  There is some evidence for a sex difference in 
muscle mass response to ST, as men increased quadriceps twice as much as women, 
after adjusting for baseline values (158). Although the majority of studies indicate 
that there is little age difference in muscle strength response to ST (157, 159), 
Lemmer et al. (160) reported an ~ 34% increase in strength in 20 – 30 year old men 
and women, which was significantly greater than the ~ 28% increase observed in 65 – 
75 old subjects.  These data suggest that in response to ST, skeletal muscle 
adaptations in older adults are comparable to the changes in younger adults.  There 
are three general phases that occur in both young and older subjects that are 
responsible for strength increase during a ST program.  First, during approximately 
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the first two weeks of a ST program, there is a strong learning effect that improves 
the subject’s ability to perform the ST exercise.  This phase of neurological 
adaptation results in improved coordination and rapid strength gains, especially if the 
strength training modality involves a high level of skill (157).  This effect can often 
be attenuated by familiarization sessions, which can prevent observed strength gains 
from being inflated, especially in older adults.  The next phase, which occurs at 
weeks ~ 3 – 7, involves increases in muscle strength without a concomitant increase 
in muscle mass.  This improvement in strength is ascribed to continuing neural 
adaptations including increased activation of the agonist muscle group (i.e. increase 
motor unit (MU) recruitment and better coordinated MU firing), improved 
involvement of synergistic muscles, decreased antagonist muscle activation, and 
increased central nervous system (CNS) drive.  Finally, the third phase of ST 
adaptations that occur at ~ 6 weeks and later results in increased strength along with a 
matching increase in muscle size. 
      Several training studies have reported muscle function changes with ST in older 
adults at the muscle fiber level.  This data show that type I and type II muscle fibers 
in older adults maintain the ability to undergo hypertrophy with ST (58, 147, 161, 
162), but some investigations found that there was only slight or no change in fiber 
areas (151, 163).  Muscle quality (i.e. strength per unit of muscle mass) has been 
shown to improve with ST in older adults (32, 137, 148).  For example, Tracy et al 
(32) reported a 14% and 16% increase in MQ in the quadriceps in response to a nine-
week ST program for older men and women, respectively.  More recently, Welle et al 
(137) examined the arm and thigh muscles of older women (62 – 72 yrs) and reported 
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that although aging might impair the hypertrophic response to ST, aging does not 
impair increases in MQ.  In that study, older women increased their knee extensor 
MQ by ~ 32% which was similar to the ~ 38% change observed in younger women 
(137). 
     However, little is known about the effect of ST on fat infiltrating into aging 
muscle, such as LDM and the accumulation of IMF. For example, Sipila et al (9) 
assigned 18 weeks of full body ST to 76 to 78-yr-old women (n = 16) and induced a 
reduction in percent thigh IMAT with ST, but no information on change in absolute 
IMF was provided. The reduced percentage of fat may have just been due to the 
increase in thigh muscle mass, which lowers the percent of fat tissue, even if the total 
mass of fat doesn’t change.  Thus, there is a need for information on the actual change 
in IMF with ST. Cuff et al (10) compared the effect of combination of ST with AT (n 
=10) on LDM in 28 obese postmenopausal women training. The combination of ST 
with AT resulted in a reduction of mid-thigh LDM in comparison to control group. 
Janssen et al (11) studied the effect of 16-week  long treatments: energy-restrictive 
diet with (n = 14) or without ST (n = 13), on mid-thigh IMF and observed a 
significant reduction in IMF in both groups. No differences were seen between diet 
alone and diet plus ST. Unfortunately, neither of these two studies can tell us the 
independent effects of ST on IMAT or LDM.  
Genetics of ST Adaptation.  
     Muscle.  Muscle mass, strength and power responses to ST vary substantially 
among individuals.  In a previous investigation from our lab, after only nine weeks of 
a highly standardized quadriceps strength training program in a healthy and 
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homogeneous group of 65 to 75 year old men and women, knee extension strength 
gains that ranged from 5 to 86 pounds (158).  In the same study, the increase in 
quadriceps muscle volume ranged from 19 to 344 cm3, and this accounted for an 
increase from <1% to about 20% of initial muscle volume. In addition, our group has 
reported muscle power changes with ST that are also quite variable (164). Others 
have also observed large variations in strength and muscle mass changes with ST.  
For example, Buchner et al. (165) reported one repetition maximum (1 RM) strength 
increases that ranged from 1 to 50 kg after 20 weeks of ST.  The standard deviations 
of these changes were larger than the mean changes and the coefficients of variation 
(CV) were > 100 %.  These data indicate that there are large inter-individual 
variations in muscle adaptation to even a very short term, highly standardized ST 
intervention.  
     These large inter-individual differences among older men and women are 
consistent with the possibility that genetic factors are involved in determining muscle 
adaptations to ST.  Beisiadecki et al. (166) observed a 1.5 to 5.2 fold divergence 
between male rat with lowest muscle strength and highest muscle strength. Reed et al. 
(167) reported that genetic effects accounted for 65% of variance in grip strength, 
even after adjusting for the effects of height, weight and age. In addition, Seeman et 
al. (168) found that 60% to 80% of inter-individual differences in lean body mass 
could be explained by genetic factors.  All of these data suggest the heredity plays an 
important role in skeletal muscle related phenotypes.  The estimation of heritability of 
a specific trait is commonly estimated by twin and family studies.  The most common 
analysis of heritability is phenotype measurement between and among sets of 
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monozygotic and dizygotic twins.  If a trait was completely determined by genetics, 
there would be correlation of 1.00 between sets of monozygotic twins.  However, 
skeletal muscle phenotypes are also influenced by many other factors beyond 
genetics, which can have an effect on the heritability estimate.  Factors such as 
shared/non-shared environmental factors, additive/dominant genetic effects, and 
measurement error can influence these heritability estimates (169).   
     Evidence from heritability studies suggest that many skeletal muscle-related 
phenotypes, including strength, FFM, and skeletal muscle fiber composition are at 
least partially explained by genetic factors.  Twin studies indicate that strength has a 
moderate to high heritability, with different studies reporting a range of 30 – 80% 
depending on the population studied.  For example, Frederiksen et al. (170) reported 
that in 1,757 Danish twin pairs aged 45 - 96 years, that handgrip strength heritability 
is 52% and is as high as 62% when examining only healthy twin pairs from the 
cohort. Grip strength has been shown to correlate strongly with other muscle groups 
with respect to strength and power.  In addition, there was no significant influence of 
age or sex in this analysis, indicating that these variables were not confounders or 
effect modifiers.  This heritability estimate is higher than previous data from 
postmenopausal female twins (171) that indicate a heritability estimate of 30%.   
Other data on strength in older male twins indicated a heritability of 65% at baseline, 
but when shared environmental factors were included in the model, this estimate 
dropped to 35% (172).  A 10-year follow up indicated a heritability estimate of only 
22% (172). More recently, Tiainen et al (173) indicated that handgrip and knee 
extension strength share a common genetic component, accounting for 14% of the 
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variance in older female twins.  However, additive genetic effects accounted for 46% 
of the variance in knee extension strength.  
     Muscle mass has also been investigated with regard to heritability using family 
and twin studies and it has been shown that estimates range from 50-90%.  Data from 
an inbred founder population (Hutterites) with detailed family pedigree records 
indicates that FFM is highly heritable (h2 = 0.76) (174).  In addition, Arden (171) 
indicated that in postmenopausal women, FFM has a heritability estimate of 56% 
when height and weight are covaried.  This is somewhat lower than what Seeman et 
al (168) reported in younger female twins, who found that FFM is ~ 80% due to 
genetic factors.  In addition, the estimation of FFM values has been shown to 
correlate more strongly among relatives than among unrelated individuals (175).  
More recent twin data confirm these estimates, finding a heritability estimate of 77% 
for FFM in both men and women (176).  Age and sex do not appear to be significant 
covariates of within pair differences.  Skeletal muscle fiber composition and enzyme 
activity are also heritable (177, 178). In order to more fully understand the specific 
contribution of specific gene variants toward explaining muscle phenotypes, an 
additional approach is to identify biologically plausible genes as a basis for 
conducting candidate gene association studies.   
      Roth et al (8) identified candidate gene polymorphisms associated with changes in 
strength and muscle mass with ST. They include angiotensin-converting enzyme gene  
(ACE), ciliary neurotrophic factor (CNTF), insulin-like growth factor I (IGF-1), IGF-
II, tumor necrosis factors (TNF) alpha and vitamin D receptors. Although numerous 
cross-sectional or longitudinal studies have showed an association between these 
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genes and skeletal muscle mass and strength (179-185), the roles that these gene 
polymorphisms play in the determination of muscle adaptations to ST are still under 
investigation. Yet, there is limited information on how specific polymorphisms may 
affect muscle adaptation to ST.  Folland et al. (186) reported that subjects with D 
alleles for the ACE gene gained greater strength than noncarriers in response to 9 
weeks of ST; and this result was later supported by Colakoglu et al. (185), but not by 
Thomis et al. (187).  Kostek et al. (149) from our group first reported carriers of 192 
allele of IGF-1 gained significantly more strength with ST than noncarriers in 
response to a 10 week ST program.  Our group has more recently found that a 
polymorphism of the alpha-actinin-3 gene (ACTN3) is associated with muscle power 
(188). Delmonico et al.(188) demonstrated that absolute change of power with ST 
was significantly higher in men with the RR polymorphism for the ACTN3 gene than 
those with XX, whereas, there was no difference in absolute power change among 
genotype groups in women at this locus. Another study from Clarkson et al. (189) 
found that those with ACTN3 XX gained greater strength than those with the RR 
polymorphism when adjusted for age and body mass. All of this available information 
and the results from future studies will help explain the genetic variations in muscle 
performances and adaptations to exercises.     
     Adipose Tissue.  The interest in regional body fat has increased considerably 
because of its association with risk for various morbid conditions and mortality rate.  
Like the heritability of muscle, adipose tissue distribution and accumulation are 
heritable and affected by specific genes. Familial resemblance in body fat distribution 
has been reported (190). Bouchard et al. (175) also demonstrated that the genetic 
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effect on total body fat was about 25% and heritability of total energy content derived 
from fat mass and fat free mass was about 15%.  Selby et al. (191) reported a 
significant genetic influence on central obesity basing on data obtained from 173 
monozygotic and 178 dizygotic pairs of male twins using skinfold measurement. In 
the Canadian fitness study, Perusse et al. (192) found a 40% transmission effect 
across generations for trunk skinfolds and limb skinfolds . Bouchard et al. (175, 193) 
further studied data from the Quebec Family Study. After the influence of total fat 
mass was taken into account, subcutaneous fat mass was found to have a heritability 
reaching ~ 40 to 50% of the residual variance and visceral abdominal fat for 
heritability of ~ 56%. The influence of major genes on regional fat phenotypes were 
suggested in two studies (194, 195).  Hasstedt et al. (194) defined a relative fat pattern 
index as the ratio of subscapular skinfolds thickness to the sum of the subscapular and 
suprailiac skinfold thickness; the 42 % of  the variance of this index can be explained 
by genetic factors. The Quebec family studies (195) also reported that 35% of the 
variance in the trunk to extremity skinfolds ratio can be explained by genetic effects 
after adjusting for total fat mass.  Thus, not only is adipose tissue heritable, but also 
the fat responses to interventions are significantly influenced by genetic factors. 
Bouchard et al.(196) conducted a series intervention studies with pairs of adult male 
identical twins to explain the genetic differences and outcome variations in the 
responses of body fat and regional body fat to interventions.  In one study (197), 12 
pairs of male homozygote twins showed considerable inter-individual differences in 
the adaptation to a 100 days of overfeeding (1000 calorie surplus per day). The 
variation observed was not randomly distributed because there were similar responses 
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within pairs.  For example, the variance between pairs was three times more than the 
variance within pairs for the gain of fat mass. The results were similar even in 
response to a short term overfeeding period (198).  In another study, Bouchard et al. 
(199) had seven pairs of male identical twins run on cycle ergometers twice a day out 
for 10 days over 93 days, while consuming a constant daily energy intake and nutrient 
intake. A daily 243 MJ energy deficit was created on average. There were large inter-
individual responses to this exercise protocol. However, the intrapair resemblance 
was still observed for body weight, body fat, percent body fat, sum of skinfolds and 
abdominal visceral fat measured by CT.  Those with the same genotypes responded to 
exercise interventions more similarly than those with different genotypes, particularly 
for body fat, abdominal visceral fat. Altogether, these data clearly show a genetic 
influence on body fat response to interventions.  
     It is well established that there is a large inter-individual variation in body fat 
responses to aerobic exercise training.  Monozygotic adult twin studies (199) revealed 
that genetic factors influence adaptations of body fat to aerobic exercise training. A 
number of studies have demonstrated significant associations of specific gene 
variations (polymorphisms) with the magnitude of body fat loss induced by aerobic 
training (14, 15, 25, 200, 201). For example, the Heritage family study (25) showed 
that white women with the adrenergic receptor (ADR) beta Arg16Arg genotype had a 
greater reduction in fat and percent fat in response to aerobic training, while results 
were mostly negative in blacks. Marcho-Azcarate et al. (14) reported ADR beta2 
Glu27Glu groups had higher plasma TG levels and respiratory quotient than the 
Gln27Gln group.  Thus, lipolysis and fat oxidation seemed to be blunted in the 
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Glu27Glu group in response to aerobic training. Phares et al. (15) observed collective 
effects of different ADR gene polymorphisms on the responses of body fat to exercise 
training.   
     Despite the absence of ST effects on IMF and LDM, few studies showed the ST- 
induced reductions in total body fat (22), abdominal subcutaneous fat and visceral fat 
(23, 202).  Trueth et al. (22) observed significant loss of total fat mass and mid-thigh 
subcutaneous fat after 16 week ST in older men. In another study, Treuth et al. (23) 
observed a reduction in intra abdominal adipose tissue without change in total body 
fat in fourteen healthy older women after 16 weeks of ST. Hunter et al. (202) 
observed the effect of 25 weeks of full body ST in older men and women. While 
women significantly lost intra abdominal adipose tissue and abdominal subcutaneous 
adipose tissue, men did not lose either of these two fat mass significantly with ST. In 
a randomized controlled trial, Binder et al (203) reported that total fat, truck fat, intra-
abdominal and abdominal subcutaneous fat did not change significantly with 6 
months of ST in frail older adults compared to a control group. Because there was no 
information in the literature on the effects of ST on intermuscular fat (IMF) and low 
density muscle (LDM), which appears to have important health implications, we 
initially addressed this issue in a pilot study involving 12 middle-aged and older 
participants of this study.  We found a reduction in IMAT with ST, but with a large 
inter-individual variation, as 9 subjects lost IMAT (from 2.2cm 2 to 24.8 cm2), 
whereas 3 subjects actually gaining IMAT after training.  A similar large inter-
individual variation was also seen in the adaptation of LDM.  These preliminary data 
suggested that the adaptation of fat to ST may be influenced by genetic factors. 
86 
 
The influence of ADR and ADR polymorphisms on lipid metabolism.  
 
     Based on the previous investigations on aerobic exercise training and its influence 
on adipose tissue metabolism, ADR gene polymorphisms seem to be a top candidate 
to explain genetic influences. 
     Adrenergic receptors (ADRs) are the protein expressed in the plasma membrane of 
adipocytes. They are the receptors for catecholamines (epinephrine and 
nonepinephrine) and therefore principally control the lipolysis.  Catecholamines 
activate the lipolytic cascade by binding to ADR β1, β2 and β3, whereas 
catecholamines binding to ADRα2 inhibits lipolytic activity. These ADRs interact 
with GTP-binding regulatory protein (G proteins) which modulate the activities of 
adenylate cyclase (AC) enzyme. All of the ADR β1, β2 and β3 are coupled with 
stimulatory G protein (Gs) while ADRα is coupled with inhibitory G protein (Gi).  
The activation of AC by ADR β receptors result in the conversion of ATP to cAMP.  
cAMP is a second messenger to activate cAMP-dependent protein kinase, which then 
phosphorylates hormone sensitive lipase (HSL) and perilipins (204). HSL and 
perilipins then break down triglycerides into free fatty acids and glycerol. Thus, the 
biological responses of catecholamines, at least partially depend on the functional 
balance between ADRβs and ADR α2 receptors. For example, both genders have a 
lower lipolytic response to catecholamines in femoral and gluteal adipocytes than in 
subcutaneous adipocytes because the latter shows increased ADRβ density and 
sensitivity and reduced ADRα2 number and affinity (205-207). Human and animal 
studies showed that a shift to higher ADR α2 / β ratio contributed to obesity and net 
lipid storage (208). 
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     ADRβ2 may be the only ADRβ receptors involved in TG metabolism in skeletal 
muscle. Ligget et al. (209) demonstrated a dominant expression of ADRβ2 in skeletal 
muscle using a ligand binding technique. Hagstorm-Toft and her colleagues (13) 
utilized a microdialysis technique to observe ADRβs regulation of lypolysis in 
skeletal muscle in healthy subjects.  Nonspecific ADRβs blocker or specific ADRβ2 
blocking agent was found to counteract the induced lipolysis and ADRβ1 blocking 
agents did not affect glycerol release at all. Moreover, the perfusion of β2-selective 
agonist induced concentration dependent increase in skeletal muscle glycerol release, 
whereas perfusion of β1 and β3 agonist did not result in any change in glycerol 
release. Thus, in skeletal muscle, ADRβ2 is the only important receptor for the 
regulation of lipolysis.  
     There exists marked large interindividual variability in the physiological responses 
to ADRs agonists and antagonists as well as functions and expressions of ADRs 
(210). This suggests genetic factors are involved in explaining variability in ADRs 
among human populations.  Because of their principal and interacting roles in the 
regulation of lypolysis and because of our special attention to fat metabolism in 
skeletal muscle, the influences of ADRβ2 and ADRα2 polymorphism on fat 
distribution, accumulation and adaptation to interventions will be reviewed in the 
subsequent section 
     ADRβ2 gene polymorphisms.  ADRβ2 gene has three polymorphisms, including 
Thr164Ile, Gln27Glu and Gly16Arg (211). Thr164Ile is a rare variant with minor 
allele frequency among populations of only about 2 to 5%. The homozygous 
individual was never found in the population suggesting this variant may be lethal. 
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When minor alleles Ile164, Glu27 and Arg16 substitute major alleles Ile164, Gln27 
and Gly16, respectively, the function of ADRβ2 is markedly changed in recombinant 
cells (29, 212).  For example, ADRβ2 Ile64 decreased high-affinity agonist binding, 
ADRβ2 Glu27 decreased agonist-promoted down-regulation and ADRβ2 Gly16 
promoted agonist-promoted down-regulation (210). However, the cell culture-based 
analysis may not provide for the environment necessary to assess relevance of a 
polymorphism in an intact human.  
      A number of clinical studies have showed the influences of ADRβ2 in fat 
distribution. Large and his colleagues (77) investigated a group of 140 women with 
large variation in body mass index (BMI). Gln27Glu polymorphism was found to be 
markedly associated with obesity. Homozygotes Glu27 had an average excess fat 
mass of 20 kg and ~ 50% larger fat cells than noncarriers (Gln/Gln). However, 
Gly16Arg was not significantly associated with obesity. When Large et al. (213) 
extended the study to non-related male subjects with a large range of BMI (213), the 
differences in fat phenotypes disappeared among ADR β2 Gln27Glu carriers, 
suggesting a potential gender-specific effect of Glu27 on fat mass. In the IRAS 
(insulin resistance and atherosclerosis) family study, Lange et al. (24) studied 
African-American (AA) and Hispanic American (HA) from three different 
geographical sites and measured subcutaneous and abdominal fat with CT.  The 
Glu27 allele was found positively associated with body mass index, visceral adipose 
tissue, but not with subcutaneous adipose tissue. The Arg16Gly polymorphism was 
not associated with any of the measures of adiposity, which is consistent with the 
finding reported by Large et al (77).  The HERITAGE family (25), however, reported 
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that Glu27 allele carriers have lower fat accumulation in obese men than noncarriers.  
And among white obese women, Gly16Gly carriers had a lower fat accumulation than 
other genotype carriers (Arg16Gly and Arg16Arg), whereas this association was 
negative in black women.  It is not clear what causes the discrepancy in the 
relationship between ADRβ genotypes and fat phenotypes. 
     The ADRβ2 polymorphisms not only influence fat distribution, but also the 
adaptation of fat to either overfeeding (214) or aerobic training (14, 15). Ukkola et al. 
(214) fed 12 pairs of identical twins a 4.2 MJ / day energy surplus for a period of 100 
days, and found that the ADRβ2 Gln27Gln carriers gained more weight and total 
subcutaneous fat than the Glu27Glu and Gln27Glu genotypes, whereas there was no 
significant difference in fat mass distribution among ADRβ3 genotype carriers. 
Macho-Azcarate et al.(14) observed higher TG, lactate level and respiratory quotient 
after aerobic training in Glu27Glu group than in Gln27Gln group. Moreover, Phares 
et al. (15) reported that Glu27 carriers lost a greater percent total body fat and trunk 
fat than noncarrers in response to a 24- wk aerobic training program.  In the 
HERITAGE family study (25), white women with Arg16Arg genotype exhibited a 
greater reduction in fat mass and percent fat mass than other genotypes carriers 
(Arg16Gly, Gly16Gly).  
     ADRα2b polymorphisms.  There were three known subtypes of ADRα, α2a, α2b 
and α2c.  These three subtypes were encoded by distinct genes located in different 
chromosomes. ADR α2a has a relatively uncommon SNP which was predominantly 
found in African Americans and has been found to be associated with salt-sensitive 
hypertension in the African American population (215). The ADRα2c also has a 
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polymorphism 10 times more common in African Americans. Heinonen et al. (78) 
first identified a polymorphism in the third loop of in ADR α2b receptor: a deletion of 
3 glutamic acids from a glutamic acids repeat element, resulting in three genotypes 
i.e. Glu12/Glu12, Glu12/Glu9 and Glu9/Glu9. In the same study, the measured basal 
metabolic rate adjusted for fat-free mass, fat mass, sex and age was lower in those 
carrying Glu9/Glu9. Lower metabolic rate was known as a risk factor for obesity 
(216). Sivenius and his colleagues (217) then investigated the effects of ADRα2b 
polymorphisms on the change of body weight in 126 non-diabetic Finnish during a 10 
year follow-up. The non-diabetic subjects with Glu9/Glu9 had a greater increase in 
their mean body weight during 5 yr follow-up than those subjects with the any other 
genotypes. The increment of body weight in Glu12/Glu9 carriers was significant. 
However, The ADR Glu12/Glu9 polymorphism was not significantly associated with 
body weight in type 2 diabetics cross-sectionally or longitudinally. Dionne et al. (218) 
genotyped 909 unrelated Caucasian women with a  wide range of BMI and did not 
find any significant differences in fat mass and visceral fat between Glu12/Glu9 
carriers. However, those carrying both ADRα2b Glu9 and ADRβ3 Arg 64 had a 9.8 
kg and 4.8% greater fat mass than ADRβ3Arg 64 only carriers. 
     The effect of a single ADRα2b polymorphism on the adaptation of fat to 
interventions has not been reported, but the interacting effects with other ADRβ 
genotypes have.  Phares et al. (15) reported that in response to aerobic training, 
Glu12/Glu12 carriers who also carried Arg64 of ADRβ3 exhibited a significantly 
greater loss in percent total body fat, percent trunk fat and fat mass than all other 
ADRα2b and ADRβ3 genotypes combined. The impact of ADRβ3 polymorphism on 
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training-induced body composition change, however, is not a consistent finding. For 
example, Garenc et al. (219) found no relationship between ADR β3 genotypes with 
the responses to exercises in the HERITAGE family study. However, the interacting 
effect between ADR α2b and ADRβ2 on the fat adaptations to exercises is 
impressive. As a result of aerobic exercise training, ADRα2b Glu9 noncarriers who 
also carried ADRβ2 Glu27 showed two to four times more reduction in percent trunk 
fat, and two times more reduction in total fat mass  than any other ADRα2b and 
ADRβ2 genotypes combined (15).  
Summary and Conclusions.   
     In summary, sarcopenia is the age-associated loss of muscle mass and muscle 
strength with adverse effects on health status and functional abilities in the elderly. 
The increasing fat infiltration into the muscle with aging, as indicated by the 
development of low density muscle (LDM) and intermuscular fat (IMF), may be an 
important aspect of sarcopenia because of its association with declines in muscle 
strength, reduced leg performances, rises in mobility limitations, and increased 
insulin resistance.  Because of the prevalence of sarcopenia and the detrimental 
effects on quality of life in the elderly, several interventions have been tried to slow 
and reverse the loss of muscle mass and strength in the elderly, such as hormonal 
intervention, nutritional supplement and strength training.  In this regard, strength 
training is considered the intervention of choice for the prevention and treatment of 
sarcopenia because of its effectiveness and safety.  Strength training can induce the 
reduction of total body fat and abdominal visceral fat (22, 23, 202).  However, little 
or no information on the effect of strength training on low density muscle and 
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intermuscular fat is reported in the literature.  It is well known that muscle adaptation 
to strength training is variable and this variation can be partially explained by specific 
gene polymorphisms. Preliminary data from our group showed similar variability for 
fat adaptation to strength training.  
     Adrenergic receptors play a principal role in the regulation of lipolysis and the 
balances between the stimulatory (ADRβs) and inhibitory receptors (ADRα2b) 
determine the efficacy of lipolysis induced by catecholamines.  Moreover, ADR gene 
polymorphisms are considered candidate genes of choice for investigating their 
influence on fat phenotypes in response to interventions, such as regular exercise. The 
associations between ADRs polymorphisms and the adaptation of fat mass to aerobic 
training have been reported and the results suggest the need to address this 
relationship with strength training as an intervention for sarcopenia.  Therefore, there 
is a need to investigate the effects of strength training on low density muscle and 
intermuscular fat, and investigate the association between this effect and specific 
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